Health and Healthcare

Teva : TEVA

All Teva Articles

450 Articles

Chris Lange | Sep 26, 2018 at 8:50 AM EDT

Short Sellers Grow More Selective on Major Pharma Stocks

The September 14 short interest data have been compared with the previous figures, and short interest moves in these selected…

Chris Lange | Sep 17, 2018 at 9:35 AM EDT

How Teva Won FDA Approval for Ajovy

Teva Pharmaceuticals shares made a solid gain on Monday morning after the company announced a critical approval by the FDA.

Chris Lange | Sep 13, 2018 at 9:55 AM EDT

Short Sellers Back Off Major Pharma Stocks

The August 31 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Sep 8, 2018 at 7:10 AM EDT

Major Biopharma Catalysts on September’s FDA Calendar

Here 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and U.S. Food…

Jon C. Ogg | Sep 7, 2018 at 8:55 AM EDT

Top Analyst Upgrades and Downgrades: Apple, Caterpillar, Costco, GW Pharma, NXP, Southwest Air, Teva, Ulta, Wells Fargo and More

The top analyst upgrades, downgrades and initiations seen on Friday include Apple, Caterpillar, Costco, GW Pharmaceuticals, NXP Semiconductors, Southwest Airlines,…

Chris Lange | Aug 27, 2018 at 7:25 AM EDT

Short Sellers Can’t Make Up Their Minds on Major Pharma Stocks

The August 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical…

Chris Lange | Aug 21, 2018 at 1:05 PM EDT

How the FDA Is Fighting the Nationwide EpiPen Shortage

The FDA is extending the expiration dates for certain EpiPens in light of the national shortage ahead of the back-to-school…

Chris Lange | Aug 16, 2018 at 1:55 PM EDT

Are Teva and Mylan Entering an EpiPen Price War to Zero?

Mylan has had a stranglehold on the market for EpiPen, but this is all changing after the FDA approved Teva…

Chris Lange | Aug 16, 2018 at 12:55 PM EDT

New Osteoarthritis Treatment Could Precipitate Another Blockbuster Drug

Teva and Regeneron both saw handy gains on Thursday after the companies posted positive topline results from their late-stage trial…

Chris Lange | Aug 10, 2018 at 9:50 AM EDT

Short Sellers Hike Bets in Major Pharma Stocks

The July 31 short interest data have been compared with the previous figures, and short interest in most of these…

Jon C. Ogg | Aug 3, 2018 at 9:20 AM EDT

Top Analyst Upgrades and Downgrades: Blue Apron, Energy Transfer, Funko, Symantec, Tesla, Teva, TripAdvisor and More

The top analyst upgrades, downgrades and other research calls from Friday include Blue Apron, Energy Transfer Partners, Funko, Symantec, Tesla, Teva…

Chris Lange | Aug 2, 2018 at 9:40 AM EDT

Teva Just Can’t Seem to Get Earnings Right

Teva shares stumbled after it released its most recent quarterly results before the markets opened on Thursday.

Chris Lange | Jul 25, 2018 at 7:35 AM EDT

Major Pharma Stocks Scare Off Short Sellers

The July 13 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Jul 12, 2018 at 8:50 AM EDT

Where Did Major Pharma Short Sellers Go?

The June 29 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Jun 27, 2018 at 1:05 PM EDT

Short Sellers Hike Bets in Major Pharma Stocks

The June 15 short interest data have been compared with the previous figures, and short interest in most of these…

1 … 5 6 7 8 9 … 30

Teva : TEVA

All Teva Articles

Short Sellers Grow More Selective on Major Pharma Stocks

How Teva Won FDA Approval for Ajovy

Short Sellers Back Off Major Pharma Stocks

Major Biopharma Catalysts on September’s FDA Calendar

Top Analyst Upgrades and Downgrades: Apple, Caterpillar, Costco, GW Pharma, NXP, Southwest Air, Teva, Ulta, Wells Fargo and More

Short Sellers Can’t Make Up Their Minds on Major Pharma Stocks

How the FDA Is Fighting the Nationwide EpiPen Shortage

Are Teva and Mylan Entering an EpiPen Price War to Zero?

New Osteoarthritis Treatment Could Precipitate Another Blockbuster Drug

Short Sellers Hike Bets in Major Pharma Stocks

Top Analyst Upgrades and Downgrades: Blue Apron, Energy Transfer, Funko, Symantec, Tesla, Teva, TripAdvisor and More

Teva Just Can’t Seem to Get Earnings Right

Major Pharma Stocks Scare Off Short Sellers

Where Did Major Pharma Short Sellers Go?

Short Sellers Hike Bets in Major Pharma Stocks

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

NVIDIA’s New Quantum‑AI Models Are Impressive — and the Market Doesn’t Seem Ready to Price the Step‑Change

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple's $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

Teva : TEVA

All Teva Articles

Short Sellers Grow More Selective on Major Pharma Stocks

How Teva Won FDA Approval for Ajovy

Short Sellers Back Off Major Pharma Stocks

Major Biopharma Catalysts on September’s FDA Calendar

Top Analyst Upgrades and Downgrades: Apple, Caterpillar, Costco, GW Pharma, NXP, Southwest Air, Teva, Ulta, Wells Fargo and More

Short Sellers Can’t Make Up Their Minds on Major Pharma Stocks

How the FDA Is Fighting the Nationwide EpiPen Shortage

Are Teva and Mylan Entering an EpiPen Price War to Zero?

New Osteoarthritis Treatment Could Precipitate Another Blockbuster Drug

Short Sellers Hike Bets in Major Pharma Stocks

Top Analyst Upgrades and Downgrades: Blue Apron, Energy Transfer, Funko, Symantec, Tesla, Teva, TripAdvisor and More

Teva Just Can’t Seem to Get Earnings Right

Major Pharma Stocks Scare Off Short Sellers

Where Did Major Pharma Short Sellers Go?

Short Sellers Hike Bets in Major Pharma Stocks

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

NVIDIA’s New Quantum‑AI Models Are Impressive — and the Market Doesn’t Seem Ready to Price the Step‑Change

Featured Reads

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple's $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not